TickerSpark Feed

nasdaq

Everything tagged "nasdaq" across the TickerSpark archives.

Should You Buy the Iron Dome Acquisition I Corp. IPO? Here's the Setup
IPOIDAC

Should You Buy the Iron Dome Acquisition I Corp. IPO? Here's the Setup

Iron Dome Acquisition I Corp. Class A Ordinary Shares (NASDAQ: IDAC) is expected to list on 2026-07-06, but the price range has not been disclosed. This is a SPAC, so the real question is whether the sponsor can find a credible target in cybersecurity, defense tech, AI, or data infrastructure. The setup favors investors who want exposure to that theme, but the main watch item is whether the deal terms and target pipeline justify the trust-account structure.

Jul 3, 20265 MIN
The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Daily market recap + weekly preview. One-click unsubscribe in every email.

Should You Buy the Vicore Pharma Holding AB IPO? Here's the Setup
IPOVCRE

Should You Buy the Vicore Pharma Holding AB IPO? Here's the Setup

Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.

Jul 2, 20265 MIN
What to Watch as AmperCap Acquisition Company Right Prices
IPOAPMCR

What to Watch as AmperCap Acquisition Company Right Prices

AmperCap Acquisition Company Right (NASDAQ: APMCR) is expected to list on 2026-06-29, but the price range has not been disclosed yet. This is a SPAC, so the key question is not operating growth — it is whether the sponsor can source a credible deal and keep the shares near trust value. Bull case: the team has cross-border M&A experience and a U.S.-Mexico focus. Bear case: no target has been announced, and SPAC dilution and deadline risk remain the main story.

Jun 26, 20265 MIN
On-Demand Research

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator